Study confirms everolimus can overcome trastuzumab resistance in HER-2 ... The Pharma Letter A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab, the active ingredient of Swiss drug major Roche's (ROG: SIX) Herceptin, has left researchers contemplating a puzzle ... |
